17,261 trials
Rabies
Primary: Rabies Virus Neutralizing Activity (RVNA) of Geometric Mean Concentration (GMC) at Study Day 8 — 4.70; 0.13; 3.30; 0.17 IU/mL
Chemotherapy-Induced Peripheral Neuropathy · Malignant Solid Neoplasm
Primary: Change in Chemotherapy-induced Peripheral Neuropathy (CIPN) From Baseline — 147.95; 135.82; 167.96; 148.45 percentage of change in CIPN
Traumatic Brain Injury
Primary: Vital Signs (Respiratory Rate) — 16.54; 16.82; 16.63; 16.42 breaths/min
Delirium in Old Age
Primary: Total Sleep Time (TST) on the First Postoperative Night — 3.91; 3.84 hours — p=0.853
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
Primary: Number of Participants With a Major Molecular Response at 12 Months — 103 Participants
Prostate Cancer
Primary: Median Duration of Response — NA; NA months
Parkinson Disease · Tremor
Primary: Change From Baseline to Week 17 on the Essential Tremor Rating Scale (TETRAS) Composite Outcome Score — -6.4; -5.3 score on a scale — p==0.2363
Heart Failure; With Decompensation
Primary: Urine Output — 5283; 2819 mL
Vaping · E-Cig Use
Primary: Percentage of Participants With Vaping Abstinence From Week 9 to 12 — 15.1; 31.8 percentage of participants — p=0.0350
Primary Open Angle Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Ocular Hypertension as Measured by Intraocular Pressure (IOP) — -1.985; -1.118; -0.827 Change in IOP mmHg
Autoimmune Hepatitis
Primary: Patients Who Achieved Complete Biochemical Response — 6; 3; 7; 3 Participants
Primary Mediastinal (Thymic) Large B-Cell Lymphoma · Recurrent Aggressive Non-Hodgkin Lymphoma · Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma
Primary: Overall Response Rate of Pembrolizumab With Concurrent Fractionated External Beam Radiotherapy (EBRT) Among Patients With Relapsed and Refractory Non-Hodgkin Lymphoma…
Liver Transplantation
Primary: Regulatory T-Cell Count — 0.44; 3.71; 3.57; 0.6 percentage of PBMC — p=< 0.01
Prurigo Nodularis · Pruritis
Primary: Phase 2a & 2b: Percent Change From Baseline in Weekly Average Worst Itch-Numeric Rating Scale (WI-NRS) Score — -50.6; -29.4; -56.2; -51.0 percentage change — p=0.0347
Carcinoma, Non-Small-Cell Lung
Primary: Phase 1: Duration of Exposure of Cabozantinib With Erlotinib — 4.43; 8.14; 8.00; 17.00 Weeks